The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Indian markets decline as Tata Motors and Nestle India shine among gainers
Indian equity markets closed lower on January 3, with the Sensex dropping 720.60 points to 79,223.11 and the Nifty falling 184 points to 24,004.75. Tata Motors and Nestle India were the top gainers, while Zomato and HDFC Bank led the losses. Market sentiment remains cautious amid concerns over slowing growth and foreign fund outflows.
global bisoprolol fumarate market poised for significant growth through 2032
The Global Bisoprolol Fumarate market is projected to grow from USD 1.3 billion in 2023 to USD 2.0 billion by 2032, with a CAGR of 7%. This medication, primarily used for hypertension and heart-related conditions, is expected to see increased demand driven by regulatory changes and market dynamics across various regions, particularly in Europe and Asia-Pacific. Key players include Merck, Pfizer, and Novartis, with a focus on understanding market trends and competitive strategies.
YSRCP MPs Face Allegations of Fraud in Kakinada Port Stake Acquisition
Andhra Pradesh police have filed a case against YSRCP MP V Vijaysai Reddy and Y Vikranth Reddy for allegedly using coercive methods to fraudulently acquire stakes in Kakinada Seaports Ltd and Kakinada SEZ Ltd. The accusations include cheating, criminal intimidation, and conspiracy, with the stakes reportedly sold at a low price to Aurobindo Realty, now Auro Infra. Senior YSRCP leader Kakani Govardhan Reddy has dismissed the allegations as "political vendetta."
Global Generic Pharmaceuticals Market Sees Growth in Simple Generics and Biosimilars
India's "Pharmaceuticals Mission" aims to boost generic production, with simple generics leading the market due to cost-effectiveness and ease of manufacturing. Cardiovascular diseases drive demand, while small molecules dominate product types. Retail pharmacies remain the preferred distribution channel, and key players like Cipla and Teva are expanding their offerings.
Allegations of Illegal Takeover of Kakinada Port Shares Against Jagan Mohan Reddy
Kakinada Seaports MD KV Rao has filed an FIR against former Andhra CM Jagan Mohan Reddy and YSRCP MP Vijay Sai Reddy for allegedly orchestrating the illegal takeover of Kakinada Port shares valued at thousands of crores. The complaint claims that 40% of the port was acquired for Rs 494 crore, significantly below its worth, and highlights accounting irregularities that deprived the government of Rs 1,000 crore in revenue.
Aurobindo Pharma reports strong growth and sets target price at 1540
Aurobindo Pharma reported an 8% YoY increase in Q2FY25 consolidated revenue to Rs. 7,796 crore, driven by strong U.S. sales and significant growth in Europe and other markets. The company’s EBITDA rose 11.6% YoY to Rs. 1,566 crore, with an improved margin of 20.1%. Geojit Financial Services maintains a BUY rating with a target price of Rs. 1,540, reflecting a positive outlook for the company.
Aurobindo Pharma rated buy with target price of 1591 by KR Choksey
KR Choksey has upgraded Aurobindo Pharma to a "BUY" rating with a target price of INR 1,591, following a stock price correction. Despite revenue meeting estimates, EBITDA and adjusted PAT fell short due to higher expenses and finance costs. The company is expected to achieve an 8.7% CAGR in revenue and a 17.7% CAGR in adjusted PAT from FY24 to FY26, supported by new product launches and improvements in its API business.
Q2 earnings reports from major companies set to impact markets today
On November 9, at least 88 companies, including major players like Asian Paints, Divis Labs, and Aurobindo Pharma, are set to release their Q2 financial results for the July-September quarter. This earnings season, which began last month, is expected to significantly influence market trends and provide insights into India's economic landscape.
global small molecule injectable drugs market trends and regional insights 2021
The global small-molecule injectable drugs market reached $188.9 billion in 2021, with a projected growth rate of 8% CAGR, expected to hit $837.8 billion by 2030. North America leads the market with a 37% share, driven by increased R&D and product approvals, while Europe is anticipated to grow the fastest due to rising demand for minimally invasive procedures. Intravenous injections accounted for 30% of the market, highlighting their critical role in rapid drug administration.
pharma sector faces growth slowdown while domestic market thrives
Pharma giants are experiencing a slowdown in earnings growth, primarily due to their reliance on the US generics market and a lack of major drug launches. Companies like Cipla, Dr Reddy's, and Aurobindo Pharma face challenges from rising competition and impending patent expirations, while midcap firms focused on the domestic market continue to thrive without the same pressures.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.